{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-009335","form_type":"8-K","ticker":"SRXH","cik":"0001471727","company_name":"SRx Health Solutions, Inc.","filed_at":"2023-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.136945+00:00","generated_at":"2026-06-17T12:37:12.713157+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Better Choice FY2022 net sales $54.7M (+19% YoY) but net loss $39.3M; cash drops sharply","bullets":["FY2022 net sales $54.7M (+19% YoY); Q4 net sales $9.3M (-15.6% YoY).","Full year net loss $39.3M vs. net income $3.4M in FY2021; includes $18.6M goodwill impairment.","Adjusted EBITDA loss widened to $(11.8)M from $(7.1)M in prior year.","Cash and equivalents fell to $3.2M from $21.7M at year-end 2021; cash burn remains a key concern.","International (+48%) and Brick & Mortar (+72%) drove growth; E-commerce (-3%) and DTC (-30%) declined."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-009335","json":"https://secwatch.observer/filing/0001628280-23-009335.json","markdown":"https://secwatch.observer/filing/0001628280-23-009335.md","text":"https://secwatch.observer/filing/0001628280-23-009335.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1471727/000162828023009335/0001628280-23-009335-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1471727/000162828023009335/bttr-20230328.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T12:37:12.713157+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5eb0c941ebfa86967d86b1fd56d8794dcdc92016","claim":"SRx Health Solutions, Inc. reported the fourth quarter ended December 31, 2022 results: revenue $9.3 million, net income $24.4 million.","evidence_excerpt":"results for the fourth quarter and year ended December 31, 2022. Lionel F. Conacher, Interim CEO of Better Choice, stated, “During the fourth quarter, net sales were sales were $9.3 million resulting in full year 2022 net sales of $54.7 million, a 19% increase versus the prior year. Our International channel delivered year-over-year net sales growth of 48% and Brick","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1471727/000162828023009335/0001628280-23-009335-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$9.3 million"},{"label":"Net income","value":"$24.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"eb349fbfd764746766cbb1c8d66fbfab35e2eddd","claim":"SRx Health Solutions, Inc. reported the year ended December 31, 2022 results: revenue $54.7 million, net income $(39.3) million.","evidence_excerpt":"and Current Reports on Form 8-K. --- EX-99.1 (EX-99.1) --- Better Choice Company Reports Fourth Quarter and Full Year 2022 Financial Results Year-to-Date Net Sales Totaled $54.7 million, an Increase of 19% Year-over-Year Year-to-Date Gross Margin of 28%, or 31% Excluding the Impact of Inventory Rationalization NEW YORK, NY, March 28, 2023 -- Better Choice","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1471727/000162828023009335/0001628280-23-009335-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$54.7 million"},{"label":"Net income","value":"$(39.3) million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}